We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alkido Pharma Inc | NASDAQ:AIKI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.56 | 3.53 | 3.98 | 0 | 01:00:00 |
BETHESDA, Md., April 6, 2015 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) -- an intellectual property development company committed to the fostering and monetization of intellectual property, today issued an update on several matters:
Anthony Hayes, Chief Executive Officer of Spherix, stated, "It has been a busy time for Spherix and we remain committed to keeping our shareholders updated on our active litigations. We are pleased that the Court granted our motion to dismiss against Cisco in Bockstar and thank our counsel for doing a great job. We further respect the Court's decisions regarding 'willful' infringement and look forward to seeing those cases now move forward and revisiting the issue of 'willfulness' later in those cases. In addition, we wish to advise our shareholders that Spherix continues to explore all monetization avenues to drive shareholder value. Spherix has been approached by third parties to purchase portions of our current patent portfolio. Whether we are able to effectuate a beneficial transaction remains uncertain, but we are focused on optimizing our assets for the benefit of our shareholders."
About Spherix
Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by active participation in the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact: |
|
Investor Relations: |
Hayden IR |
Brett Mass, Managing Partner | |
Phone: (646) 536-7331 | |
Email: brett@haydenir.com | |
www.haydenir.com | |
Spherix: |
Phone: (703) 992-9325 |
Email: info@spherix.com | |
www.spherix.com |
Logo - http://photos.prnewswire.com/prnh/20131104/PH08853LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spherix-continues-monetization-effort-300061077.html
SOURCE Spherix Incorporated
Copyright 2015 PR Newswire
1 Year Alkido Pharma Chart |
1 Month Alkido Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions